Skip to main navigation menu Skip to main content Skip to site footer
Brazilian Journal of Clinical Medicine and Review

Health Review

Vol. 3 No. 1 (2025): January/December - 2025

Non-Motor Features of Parkinson Disease: A New Clinical State of The Art

DOI
https://doi.org/10.52600/2965-0968.bjcmr.2025.3.1.bjcmr29
Submitted
November 24, 2024
Published
2025-03-15

Abstract

Parkinson's disease (PD) is a multisystemic, progressive disorder in which there is dopaminergic neuronal degeneration, with involvement of the substantia nigra and consequently the development of pre-motor, non-motor and motor symptoms, leading to a difficulty in the patient's quality of life. The aim of this study was to carry out a narrative review of the literature to update the state of the art on the non-motor symptoms of PD. A review of the literature from the last 10 years was carried out, highlighting mainly the prodromal manifestations of PD, such as sleep symptoms, sensory symptoms, neuropsychiatric and autonomic symptoms in their prodromal phases and their relationship with motor symptoms. Thus, we reiterate that premotor manifestations precede motor symptoms by up to 20 years and, consequently, the diagnosis of this neurodegenerative disease with a guarded prognosis. Thus, more longitudinal studies are needed looking at the prodromal symptoms of PD to gain a broad understanding and consequent early diagnosis of the disease, in order to provide biomarkers and support for early treatment with an improved prognosis for individuals living with this neurodegenerative condition.

References

  1. Baldelli L, Schade S, Jesús S, Schreglmann SR, Sambati L, Gómez-Garre P, Halsband C, Calandra-Buonaura G, Adarmes-Gómez AD, Sixel-Döring F, Zenesini C, Pirazzini C, Garagnani P, Bacalini MG, Bhatia KP, Cortelli P, Mollenhauer B, Franceschi C; PROPAG-AGEING consortium; Mir P, Trenkwalder C, Provini F. Heterogeneity of prodromal Parkinson symptoms in sib-lings of Parkinson disease patients. NPJ Parkinsons Dis. 2021 Sep 7;7(1):78. doi: 10.1038/s41531-021-00219-1. PMID: 34493736; PMCID: PMC8423761.
  2. Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, Sugiyama H, Sawada H. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS One. 2014 Jun 2;9(6):e94944. doi: 10.1371/journal.pone.0094944. PMID: 24887491; PMCID: PMC4041721.
  3. Leite Silva ABR, Gonçalves de Oliveira RW, Diógenes GP, de Castro Aguiar MF, Sallem CC, Lima MPP, de Albuquerque Filho LB, Peixoto de Medeiros SD, Penido de Mendonça LL, de Santiago Filho PC, Nones DP, da Silva Cardoso PMM, Ribas MZ, Galvão SL, Gomes GF, Bezerra de Menezes AR, Dos Santos NL, Mororó VM, Duarte FS, Dos Santos JCC. Premotor, nonmotor and motor symptoms of Parkinson's disease: a new clinical state of the art. Ageing Res Rev. 2023;84:101834. doi: 10.1016/j.arr.2022.101834.
  4. Ba F, Obaid M, Wieler M, Camicioli R, Martin WR. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. Can J Neurol Sci. 2016 Mar;43(2):261-7. doi: 10.1017/cjn.2015.328. PMID: 26949837.
  5. Abraham A, Bay AA, Ni L, Schindler N, Singh E, Leeth E, Bozorg A, Hart AR, Hackney ME. Gender differences in motor and non-motor symptoms in individuals with mild-moderate Parkinson's disease. PLoS One. 2023 Jan 11;18(1):e0272952. doi: 10.1371/journal.pone.0272952. PMID: 36630320; PMCID: PMC9833587.
  6. Halli-Tierney AD, Luker J, Carroll DG. Parkinson disease. Am Fam Physician. 2020 Dec 1;102(11):679-691. PMID: 33252908.
  7. Mallet D, Dufourd T, Decourt M, Carcenac C, Bossù P, Verlin L, Fernagut PO, Benoit-Marand M, Spalletta G, Barbier EL, Carnicella S, Sgambato V, Fauvelle F, Boulet S. A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models. J Clin Invest. 2022 Feb 15;132(4):e146400. doi: 10.1172/JCI146400. PMID: 34914634; PMCID: PMC8843749.
  8. LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat Disord. 2020;80:S7-S12.
  9. Poewe W. Non‐motor symptoms in Parkinson’s disease. Eur J Neurol. 2008;15:14-20.
  10. De Rui M, Inelmen EM, Trevisan C, Pigozzo S, Manzato E, Sergi G. Parkinson’s disease and the non-motor symptoms: hy-posmia, weight loss, osteosarcopenia. Aging Clin Exp Res. 2020;32:1211-1218.
  11. Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018 May 21;208(9):404-409. doi: 10.5694/mja17.00993. PMID: 29764353.
  12. Schapira A, Chaudhuri K, Jenner P. Características não motoras da doença de Parkinson. Nat Rev Neurosci. 2017;18:435–450. doi: 10.1038/nrn.2017.62.
  13. Xiao Q, Chen S, Le W. Hyposmia: a possible biomarker of Parkinson's disease. Neurosci Bull. 2014;30(1):134–140.
  14. Kim JJ, Bandres-Ciga S, Heilbron K, 23andMe Research Team, Blauwendraat C, Noyce AJ. Bidirectional relationship between olfaction and Parkinson's disease. medRxiv. 2023 Oct 18;2023.10.18.23297218. doi: 10.1101/2023.10.18.23297218.
  15. Mao CJ, Wang F, Chen JP, Yang YP, Chen J, Huang JY, Liu CF. Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson's disease. Clin Interv Aging. 2017;12:1637–1644. doi: 10.2147/CIA.S147588.
  16. Mostofi A, Morgante F, Edwards MJ, Brown P, Pereira EAC. Pain in Parkinson's disease and the role of the subthalamic nucleus. Brain. 2021 May;144(5):1342–1350. doi: 10.1093/brain/awab001.
  17. Cattaneo C, Jost WH. Pain in Parkinson's Disease: Pathophysiology, Classification and Treatment. J Integr Neurosci. 2023;22(5):132. doi: 10.31083/j.jin2205132.
  18. Tseng MT, Lin CH. Pain in early-stage Parkinson's disease: implications from clinical features to pathophysiology mecha-nisms. J Formos Med Assoc. 2017;116(8):571–581. doi: 10.1016/j.jfma.2017.04.024.
  19. Ma B, Zhang J, Cui Y, Gao H. The anatomy and clinical significance of sensory disturbance in Parkinson's disease. J Integr Neurosci. 2023;22(3):56. doi: 10.31083/j.jin2203056.
  20. Nieto-Escamez F, Obrero-Gaitán E, Cortés-Pérez I. Visual dysfunction in Parkinson's disease. Brain Sci. 2023 Aug;13(8):1173. doi: 10.3390/brainsci13081173.
  21. Oppo V, Melis M, Melis M, Tomassini Barbarossa I, Cossu G. "Smelling and tasting" Parkinson's disease: using senses to improve the knowledge of the disease. Front Aging Neurosci. 2020;12:43. doi: 10.3389/fnagi.2020.00043.
  22. Roos DS, Oranje OJM, Freriksen AFD, Berendse HW, Boesveldt S. Flavor perception and the risk of malnutrition in patients with Parkinson's disease. J Neural Transm (Vienna). 2018;125(6):925–930. doi: 10.1007/s00702-018-1862-8.
  23. Stefani A, Högl B. Sleep in Parkinson's disease. Neuropsychopharmacology. 2020 Jan;45(1):121–128. doi: 10.1038/s41386-019-0448-y.
  24. Malhotra RK. Neurodegenerative disorders and sleep. Sleep Med Clin. 2018 Mar;13(1):63–70. doi: 10.1016/j.jsmc.2017.09.006.
  25. Hunt J, Coulson EJ, Rajnarayanan R, et al. Sleep and circadian rhythms in Parkinson's disease and preclinical models. Mol Neurodegener. 2022;17:2. doi: 10.1186/s13024-021-00504-w.
  26. Diaconu Ș, Irincu L, Ungureanu L, Ciopleiaș B, Țînț D, Falup-Pecurariu C. Restless Legs Syndrome in Parkinson's Disease. J Pers Med. 2023 Jun;13(6):915. doi: 10.3390/jpm13060915.
  27. Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Restless legs syndrome and leg motor restlessness in Parkinson's disease. Parkinsons Dis. 2015;2015:490938. doi: 10.1155/2015/490938.
  28. Maggi G, Vitale C, Cerciello F, Santangelo G. Sleep and wakefulness disturbances in Parkinson's disease: a meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Med Rev. 2023;68:101759. doi: 10.1016/j.smrv.2023.101759.
  29. Diaconu Ș, Falup-Pecurariu O, Țînț D, Falup-Pecurariu C. REM sleep behaviour disorder in Parkinson's disease (Review). Exp Ther Med. 2021 Aug;22(2):812. doi: 10.3892/etm.2021.10244.
  30. Roheger M, Kalbe E, Liepelt-Scarfone I. Progression of cognitive decline in Parkinson's disease. J Parkinsons Dis. 2018;8(2):183–193. doi: 10.3233/JPD-181306.
  31. Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2020;73:85–93. doi: 10.1016/j.parkreldis.2019.10.002.
  32. Das T, Hwang JJ, Poston KL. Episodic recognition memory and the hippocampus in Parkinson's disease: A review. Cortex. 2019 Feb;113:191–209. doi: 10.1016/j.cortex.2018.11.021.
  33. Angelopoulou E, Bougea A, Papageorgiou SG, Villa C. Psychosis in Parkinson's Disease: A Lesson from Genetics. Genes (Basel). 2022 Jun;13(6):1099. doi: 10.3390/genes13061099.
  34. Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81–95. doi: 10.1038/nrneurol.2016.200.
  35. Hermanowicz N, Edwards K. Parkinson's disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015 Oct;21(10 Suppl):s199–s206.
  36. Aveni K, Ahmed J, Borovsky A, McRae K, Jenkins ME, Sprengel K, Fraser JA, Orange JB, Knowles T, Roberts AC. Predictive language comprehension in Parkinson's disease. PLoS One. 2023 Feb;18(2):e0262504. doi: 10.1371/journal.pone.0262504.
  37. Liu L, Luo XG, Dy CL, Ren Y, Feng Y, Yu HM, Shang H, He ZY. Characteristics of language impairment in Parkinson's disease and its influencing factors. Transl Neurodegener. 2015 Jan;4(1):2. doi: 10.1186/2047-9158-4-2.
  38. Robinson GA, Campbell L, Ceslis A. A goal intervention improves language fluency: evidence from Parkinson's disease and healthy aging. Medicines (Basel). 2021 Mar;8(3):15. doi: 10.3390/medicines8030015.
  39. Akhmadeeva GN, Magzhanov RV, Tayupova GN, Bajtimerov AR, Hidijatova IM. Depressiia i trevozhnost' pri bolezni Parkinsona [Anxiety and depressive disorders in Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(1. Vyp. 2):54–58. doi: 10.17116/jnevro20171171254-58.
  40. Upneja A, Paul BS, Jain D, Choudhary R, Paul G. Anxiety in Parkinson's disease: correlation with depression and quality of life. J Neurosci Rural Pract. 2021;12(2):323–328. doi: 10.1055/s-0041-1722840.
  41. Wu PL, Lee M, Huang TT. Effectiveness of physical activity on patients with depression and Parkinson's disease: a systematic review. PLoS One. 2017 Jul;12(7):e0181515. doi: 10.1371/journal.pone.0181515.
  42. Rudisch DM, Krasko MN, Burdick R, Broadfoot CK, Rogus-Pulia N, Ciucci MR. Dysphagia in Parkinson disease: Part I - Pathophysiology and diagnostic practices. Curr Phys Med Rehabil Rep. 2023;11(2):176–187. doi: 10.1007/s40141-023-00392-9.
  43. Umemoto G, Furuya H. Management of dysphagia in patients with Parkinson's disease and related disorders. Intern Med. 2020;59(1):7–14. doi: 10.2169/internalmedicine.2373-18.
  44. Cosentino G, Avenali M, Schindler A, Pizzorni N, Montomoli C, Abbruzzese G, Antonini A, Barbiera F, Benazzo M, Benarroch EE, Bertino G, Cereda E, Clavè P, Cortelli P, Eleopra R, Ferrari C, Hamdy S, Huckabee ML, Lopiano L, Marchese Ragona R, et al. A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. J Neurol. 2022 Mar;269(3):1335–1352. doi: 10.1007/s00415-021-10739-8.
  45. Metzger JM, Emborg ME. Autonomic dysfunction in Parkinson disease and animal models. Clin Auton Res. 2019 Aug;29(4):397–414. doi: 10.1007/s10286-018-00584-7.
  46. Hogg E, Frank S, Oft J, Benway B, Rashid MH, Lahiri S. Urinary tract infection in Parkinson's disease. J Parkinsons Dis. 2022;12(3):743–757. doi: 10.3233/JPD-213103.
  47. Wang J, Cao R, Huang T, Liu C, Fan Y. Urinary dysfunction is associated with nigrostriatal dopaminergic degeneration in early and untreated patients with Parkinson's disease. Parkinsons Dis. 2020;2020:4981647. doi: 10.1155/2020/4981647.
  48. Santa Rosa Malcher CM, Roberto da Silva Gonçalves Oliveira K, Fernandes Caldato MC, Lopes Dos Santos Lobato B, da Silva Pedroso J, de Tubino Scanavino M. Sexual disorders and quality of life in Parkinson's disease. Sex Med. 2021;9(1):100280. doi: 10.1016/j.esxm.2020.10.008.
  49. Kinateder T, Marinho D, Gruber D, Hatzler L, Ebersbach G, Gandor F. Sexual dysfunctions in Parkinson's disease and their influence on partnership-data of the PRISM study. Brain Sci. 2022 Feb;12(2):159. doi: 10.3390/brainsci12020159.
  50. de Rooy FBB, Buhmann C, Schönwald B, Martinez-Martin P, Rodriguez-Blazquez C, Putter H, Elzevier HW, van der Plas AA. Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. J Neural Transm (Vienna). 2019 Oct;126(10):1273–1280. doi: 10.1007/s00702-019-02053-5.
  51. Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal dysfunction in Parkinson's disease. J Clin Med. 2021;10(3):493. doi: 10.3390/jcm10030493.
  52. Han MN, Finkelstein DI, McQuade RM, Diwakarla S. Gastrointestinal dysfunction in Parkinson's disease: current and potential therapeutics. J Pers Med. 2022 Feb;12(2):144. doi: 10.3390/jpm12020144.
  53. Öksüz N, Öztürk Ş, Doğu O. Future prospects in Parkinson's disease diagnosis and treatment. Noro Psikiyatr Ars. 2022;59(Suppl 1):S36–S41. doi: 10.29399/npa.28169.
  54. Gouda NA, Elkamhawy A, Cho J. Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update. Biomedicines. 2022 Feb;10(2):371. doi: 10.3390/biomedicines10020371.

Most read articles by the same author(s)

1 2 > >>